Abstract
The expression of neutral glycosphingolipids and gangliosides has been studied in human skeletal and heart muscle using indirect immunofluorescence microscopy. Transversal and longitudinal cryosections were immunostained with specific monoclonal and polyclonal antibodies against the neutral glycosphingolipids lactosylceramide, globoside, Forssman glycosphingolipid, gangliotetraosylceramide, lacto-N-neotetraosylceramide and against the gangliosides GM3(Neu5Ac) and GM1(Neu5Ac). To confirm the lipid nature of positive staining, control sections were treated with methanol and chloroform:methanol (1:1) before immunostaining. These controls were found to be either negative or strongly reduced in fluorescence intensity, suggesting that lipid bound oligosaccharides were detected. In human skeletal muscle, lactosylceramide was found to be the main neutral glycosphinogolipid. Globoside was moderately expressed, lacto-N-neotetraosylceramide and gangliotetraosylceramide were minimally expressed and Forssman glycosphingolipid was not detected in human skeletal muscle. The intensities of the immunohistological stains of GM3 and GM1 correlated to the fact that GM3 is the major ganglioside in skeletal muscle whereas GM1 is expressed only weakly. In human heart muscle globoside was the major neutral glycosphingolipid. Lactosylceramide and lacto-N-neotetraosylceramide were moderately expressed, gangliotetraosylceramide was weakly expressed and the Forssman glycosphingolipid was not expressed at all in cardiac muscle. GM3 and GM1 were detected with almost identical intensity. All glycosphingolipids were present in plasma membranes as well as at the intracellular level.
Similar content being viewed by others
References
Ledeen RW, Yu RK (1982)Methods Enzymol 83:139–91.
Schauer R (1988)Adv Exp Med Biol 228:47–72.
Stults CLM, Sweeley CC, Macher BA (1989)Methods Enzymol 179:167–214.
Karlsson KA (1989)Ann Rev Biochem 58:309–50.
Paulson JC (1985) InThe Receptors, Vol. II (Conn PM, ed.) pp. 131–219. Orlando: Academic Press, p 131–219.
Igarashi Y, Nojiri H, Hanai N, Hakomori S-I (1989)Methods Enzymol 179:521–41.
Hakomori S-I (1990)J Biol Chem 265:18713–16.
Zeller CB, Marchase RB (1992)Am J Physiol 262 (Cell Physiol 31): C1341–55.
Hakomori S-I (1981)Ann Rev Biochem 50:733–64.
Svennerholm L, Bruce Å, Månsson J-E, Rynmark BM, Vanier M-T (1972)Biochim Biophys Acta 280:626–36.
Nakamura K, Ariga T, Yahagi T, Miyatake T, Suzuki A, Yamakawa T (1983)J Biochem 94:1359–65.
Chien J-L, Hogan EL (1980)Biochim Biophys Acta 620:454–61.
Puro K, Maury P, Huttunen JK (1969)Biochim Biophys Acta 187:230–35.
Marcus DM, Janis R (1970)J Immunol 104:1530–39.
Katz HR, Austen KF (1986)J Immunol 136:3819–24.
Symington FW, Murray WA, Bearman SI, Hakomori S-I (1987)J Biol Chem 262:11356–63.
Symington FW (1989)J Immunol 142:2784–90.
Gillard BK, Thurmon LT, Marcus DM (1993)Glycobiology 3:57–67.
Gillard BK, Heath JP, Thurmon LT, Marcus DM (1991)Exp Cell Res 192:433–44.
Čačić M, Neumann U, Kračun I, Müthing J (1993)Biol Chem Hoppe-Seyler 374:841.
Kasai M, Iwamori M, Nagai Y, Okumura K, Tada T (1980)Eur J Immunol 10:175–80.
Bethke U, Müthing J, Schauder B, Conradt P, Mühlradt PF (1986)J Immunol Methods 89:111–16.
Müthing J, Mühlradt PF (1988)Anal Biochem 173:10–17.
Müthing J, Neumann U (1993)Biomed Chromatogr 7:158–61.
Müthing J, Maurer U, Šoštarić K, Neumann U, Brandt H, Duvar S, Peter-Katalinić J, Weber-Schürholz S (1994)J Biochem 115:248–56.
Müthing J, Steuer H, Peter-Katalinić J, Marx U, Bethke U, Neumann U, Lehmann J (1994)J Biochem 116:64–73.
Müthing J, Pörtner A, Jäger V (1992)Glycoconjugate J 9:265–73.
Young WW Jr., Portoukalian J, Hakomori S-I (1981)J Biol Chem 256:10967–72.
Bethke U, Kniep B, Mühlradt PF (1987)J Immunol 138:4329–35.
Suzuki A, Yamakawa T (1981)J Biochem 90:1541–4.
Chien J-L, Hogan EL (1980) InCell Surface Glycolipids (Sweeley CC, ed.) pp. 135–48. NY: American Chemical Society.
Chien J-L, Hogan EL (1983)J Biol Chem 258:10727–30.
Dasgupta S, Chien J-L, Hogan EL, van Halbeek H (1991)J Lipid Res 32:499–506.
Leskawa KC, Hogan EL (1990)Mol Cell Biochem 96:163–73.
Lassaga FE, Albarracin de Lassaga I, Caputto R (1972)J Lipid Res 13:810–15.
Iwamori M, Nagai Y (1978)J Biochem 84:1609–15.
Iwamori M, Nagai Y (1981)J Biochem 89:1253–64.
Clark GF, Smith PB (1983)Biochim Biophys Acta 755:56–64.
Nakamura K, Nagashima M, Sekine M, Igarashi M, Ariga T, Atsumi T, Miyatake T, Suzuki A, Yamakawa T (1983)Biochim Biophys Acta 752:291–300.
Ariga T, Sekine M, Nakamura K, Igarashi M, Nagashima M, Miyatake T, Suzuki A, Yamakawa T (1983)J Biochem 93:889–93.
Leskawa KC, Buse PE, Hogan EL, Garvin AJ (1984)Neurochem Pathol 2:19–29.
Levis GM, Karli JN, Moulopoulos SD (1979)Lipids 14:9–14.
Ogawa K, Abe T, Yoshimura K (1985)Jpn J Exp Med 55:123–27.
Li Y-T, Månson J-E, Vanier M-T, Svennerholm L (1973)J Biol Chem 248:2634–36.
Maurer U, Weber-Schürholz S, Neumann U, Brandt H, Müthing J (1993)Biol Chem Hoppe-Seyler 374:951–52.
Chan K-FJ (1989)J Biol Chem 264:18632–37.
Chan K-FJ, Liu Y (1991)Glycobiology 1:193–203.
Slomiany BL, Liu J, Fekete Z, Yao P, Slomiany A (1992)Int J Biochem 24:1289–94.
Hilbush BS, Levine JM (1991)Proc Natl Acad Sci USA 88:5616–20.
Reuter G, Schauer R (1988)Glycoconjugate J 5:133–35.
IUPAC-IUB Commission on Biochemical Nomenclature (1977)Eur J Biochem 79:11–21.
Svennerholm L (1963)J Neurochem 10:613–23.
Author information
Authors and Affiliations
Additional information
Abbreviations used: BSA, bovine serum albumin; DAPI, 4′,6-diamidine-2-phenylindole-dihydrochloride; DTAF, fluorescein isothiocyanate derivative; GSL(s), glycosphingolipid(s); Neu5Ac,N-acetylneuraminic acid [50]; PBS, phosphate buffered saline. The designation of the following glycosphingolipids follows the IUPAC-IUB recommendations [51] and the nomenclature of Svennerholm [52]. Lactosylceramide or LacCer, Galβ1-4Glcβ1-1Cer; gangliotriaosylceramide or GgOse3Cer, GalNAcβ1-4Galβ1-4Glcβ1-1Cer; globotriaosylceramide or GbOse3Cer, Galαl-4Galβl-4Glcβl-1Cer; gangliotetraosylceramide or GgOse4Cer, Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer; globotetraosylceramide or GbOse4Cer, GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer; lacto-N-neotetraosylceramide or nLcOse4Cer, Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer; Forssman GSL or GbOse3Cer, GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Gleβ1-1Cer; GM3, II3Neu5Ac-LacCer; GM2, II3Neu5Ac-GgOse3Cer; GM1, II3Neu5Ac-GgOse4Cer; GD3 II3(Neu5Ac)2-LacCer; GD2, II3(Neu5Ac)2-GgOse3Cer; GD1a, IV3Neu5Ac, II3Neu5Ac-GgOse4Cer; GD1b, II3(Neu5Ac)2-GgOse4Cer.
Rights and permissions
About this article
Cite this article
Čačić, M., Müthing, J., Kračun, I. et al. Expression of neutral glycosphingolipids and gangliosides in human skeletal and heart muscle determined by indirect immunofluorescence staining. Glycoconjugate J 11, 477–485 (1994). https://doi.org/10.1007/BF00731284
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00731284